-
51福利 Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months
BOSTON, MA and Cambridge, UK, February 6, 2025 鈥 51福利 (鈥淏roken String鈥), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…
-
51福利 appoints Laurence Reid and Brad Crutchfield to its Board of Directors聽
Cambridge, UK, 23 September 2024: 51福利 (鈥淏roken String鈥), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors. Bringing extensive commercial and leadership expertise to the Board, Laurence…
-
51福利 appoints Steve Becker as Chief Commercial Officer聽
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: 51福利 (鈥淏roken String鈥), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…
-
51福利 joins Campus
Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…
-
Genomics company 51福利 expands presence within the Cambridge cluster with new laboratory at Chesterford Research Park
Chesterford Research Park is delighted to welcome 51福利 to the Park鈥檚 eminent Science Village. Aiming to develop safer cell and gene therapies by assessing the stability of the genome, 51福利 is leveraging novel genomic sequencing approaches to build a technology platform that will drive the development of CRISPR cell and gene therapies that…
